

"Express Mail" Label No. EV326936905US
Date of Deposit March 20, 2006


I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PATENT

Attorney Docket No.: 086035-000000US

Client Reference No.: PA34271US-031/wl


Aurora Lowell



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Harald STEIN *et al.*

Application No.: 10/612,832

Filed: July 1, 2003

For: AGENT FOR USE IN
DIAGNOSTICS AND THERAPY

Examiner: Lei Yao

Art Unit: 1642

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references in compliance with the requirements of 37 CFR §1.98(a)(2) are enclosed.

Also enclosed is a copy of the Search/Examination report corresponding to the European application.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

CERTIFICATION

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Milan M. Vinnola
Reg. No. 45,979

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 303-571-4000
Fax: 303-571-4321



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/612,832
				Filing Date	July 1, 2003
				First Named Inventor	Stein, Harald
				Art Unit	1642
				Examiner Name	Lei Yao
Sheet	1	of	1	Attorney Docket Number	086035-000000US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	AB	WO	94/04189		03/03/1994	STEIN, et al.		<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BA	TERENZI, et al. "Anti-CD30 (BER-H2) immunotoxins containing the type1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30 ⁺ tumour cells <i>in vitro</i> and in SCID mice"; <i>British Journal of Haematology</i> (1996) 92: 872-879.	<input type="checkbox"/>
	BB	CHEONG, et al. "Affinity enhancement of bispecific antibody against two different epitopes in the same antigen"; <i>Biochemical and Biophysical Research Communications</i> ; Vol. 173, No. 3, (1990), 795-800.	<input type="checkbox"/>
	BC	LU, et al. "Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2"; <i>Journal of Immunological Methods</i> ; 230 (1999) 159-171.	<input type="checkbox"/>
	BD	KLIMKA, et al. "Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning"; <i>British Journal of Cancer</i> (2000) 83(2), 252-260.	<input type="checkbox"/>
	BE	DONG, et al. "Human CD30: Structural implications from epitope mapping and modeling studies"; <i>J. Mol. Recognit</i> (2003); 16: 28-36.	<input type="checkbox"/>
	BF	DÜRKOP, et al. "Structure of the Hodgkin's lymphoma-associated human CD30 gene and the influence of a microsatellite region on its expression in CD30 ⁺ cell lines"; <i>Biochimica et Biophysica Acta</i> ; 1519 (2001); 185-191.	<input type="checkbox"/>
	BG	HANSEN, et al. "Ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5"; <i>The FASEB Journal</i> ; Express Article 10.1096/fg.03-0901 fje. Published online March 19, 2004.	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.